Announcements Trials
Browse Landscape

Status

Temporarily not available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Conditions

Prostatic Neoplasms 16Neoplasms 11Neuroblastoma 9Lambert-Eaton Myasthenic Syndrome 7Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 6Leukemia 6Carcinoma, Hepatocellular 6Pheochromocytoma 5Lymphoma 5Leukemia, Myeloid, Acute 5Osteosarcoma 4Neuroendocrine Tumors 4Myelodysplastic Syndromes 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Glioblastoma 4Sarcoma 3Precancerous Conditions 3Paraganglioma 3Pancreatic Neoplasms 3Neuroectodermal Tumors, Primitive 3Insulinoma 3Immunologic Deficiency Syndromes 3Hematologic Neoplasms 3Glioma 3Carcinoid Tumor 3Breast Neoplasms 3Sarcoma, Ewing 2

Interventions

pembrolizumab 1Insulin Infusion Systems 1Gemcitabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Expanded_access × KRAS G12V Mutant Advanced Epithelial Cancers × Clear all
NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡